Diagnostic testing company Quidel Corporation (NASDAQ:QDEL) said on Thursday that it expects total revenues in the range of USD505m to USD510m for the third quarter of 2021.
This marks an improvement in the 6% and 7% range from the total revenues of USD476.1m generated in the third quarter of 2020.
For the Q3 of 2021, the company has delivered over 45m SARS tests, a rise of 135% over the Q3 2020.
COVID-19 revenues for Q3 2021 are expected to be about USD406m, up over COVID-19 revenues of USD375.7m for the Q3 2020.
The company added that the preliminary results are based on management's initial analysis of operations for the quarter ended 30 September 2021. It plans to issue full financial results for the fiscal third quarter of 2021 in November.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development